The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
about
Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Which therapies will move to the front line for multiple myeloma?The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.The safety of daratumumab for the treatment of multiple myeloma.New developments in the treatment of multiple myeloma - clinical utility of daratumumab.The multi-faceted potential of CD38 antibody targeting in multiple myeloma.Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab.Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.Daratumumab (anti-CD38) induces loss of CD38 on red blood cells.Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study.CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of ResistancePharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaTypical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
P2860
Q36363958-2FDC348E-2792-45BD-B8C3-BE60B81A5620Q38733592-B2EDF788-5A71-4504-98CD-AC132753D408Q38745915-C675CE62-F6CE-46C1-980C-D430EBF54D39Q38793959-FAA72745-DAF0-49C3-B7A5-62075AF9AEA5Q38820002-49DEA3D0-A275-4AB0-84D9-FEFA6F7FA59EQ39200031-CB7DF044-C91A-4D1D-8670-68680F00C453Q47344786-FD711270-82EC-47D8-A40F-A20DFF503745Q47614728-90CE219B-9272-439D-81F9-F3904D0C1D5EQ47688664-2377E077-57CC-4F27-B55A-0C2BC9C0AEE0Q49539698-5B128953-5A53-421D-824C-C06AB1FF0D1DQ49950717-93CE7EB8-0367-47CF-92D6-F6BC72578BF9Q49995833-8A1B5550-B85E-4041-A84B-2607A113F1AEQ50211747-675C79B6-C555-40FB-B8B6-020B308B8C00Q55358807-71A77E20-5791-4E65-A619-41AE17703708Q57191729-5F243C69-74EA-465E-945D-FE85667AEFC5Q58099961-B786D5BD-6F4B-4184-81CA-1EABF8F31F35Q58804941-71C18C03-1DD2-444E-BC8D-9B37E661DC1A
P2860
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@en
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@nl
type
label
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@en
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@nl
prefLabel
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@en
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@nl
P2093
P2860
P50
P356
P1476
The Therapeutic CD38 Monoclona ...... ceptor-Mediated Cross-Linking.
@en
P2093
J H Marco Jansen
Jeroen J Lammerts van Bueren
Maaike Nederend
Marije B Overdijk
Peter Boross
P2860
P304
P356
10.4049/JIMMUNOL.1501351
P407
P577
2016-06-17T00:00:00Z